Press Releases

KemPharm® is a clinical stage, specialty pharmaceutical company engaged in the development and discovery of proprietary prodrugs that are designed to be improved versions of widely prescribed and FDA approved products.

Press Releases

News Releases

Date Title and Summary
Toggle Summary KemPharm Reports First Quarter 2021 Financial Results
Corporate and Regulatory Highlights AZSTARYS TM NDA approved by the FDA on March 2, 2021 Announced amendment to Licensing Agreement with Gurnet Point Capital affiliate following FDA approval of AZSTARYS Received FDA clearance to initiate KP879 clinical program for the treatment of Stimulant Use
Toggle Summary KemPharm Announces Serdexmethylphenidate (SDX) Has Been Classified as a Schedule IV Controlled Substance by the DEA
KP879, KemPharm’s Lead Product Candidate Based on SDX and Intended for the Treatment of Stimulant Use Disorder (SUD), Could Be Schedule IV, If Approved by the FDA CELEBRATION, Fla. , May 07, 2021 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ: KMPH), a specialty pharmaceutical company engaged in the
Toggle Summary KemPharm to Report First Quarter 2021 Results
Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Thursday, May 13, 2021 , 4:30 p.m. ET CELEBRATION, Fla. , May 06, 2021 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs,
Toggle Summary KemPharm Confirms Receipt of $10 Million Milestone Payment for FDA Approval of AZSTARYS™ Per License Agreement with Affiliate of Gurnet Point Capital
Eligible to Receive Additional Near-Term $10 Million Milestone Payment Following DEA Scheduling of SDX CELEBRATION, Fla. , April 21, 2021 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ: KMPH), a specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, today
Toggle Summary KemPharm Announces Amendment to Licensing Agreement with Gurnet Point Capital Affiliate Following FDA Approval of AZSTARYS™
Amendment Increases Total Potential Regulatory and Sales Milestone Payments to $590 Million , and Adds a New Top-Level Tier for Royalties on U.S. Net Sales Conference Call and Live Audio Webcast Scheduled for Today, Thursday, April 8 , at 4:30 p.m. ET CELEBRATION, Fla.
Toggle Summary KemPharm Reports Fourth Quarter and Full-Year 2020 Financial Results
Corporate and Regulatory Highlights: AZSTARYS™ NDA approved by the FDA on March 2, 2021 Co-hosted “KP415 Market Opportunity and Commercialization Strategy” Investor Event with Corium, Inc. Received FDA clearance to initiate KP879 clinical program for the treatment of Stimulant Use Disorder
Toggle Summary KemPharm to Report Fourth Quarter and Full Year 2020 Financial Results
Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Thursday, March 11, 2021 , 4:30 p.m. ET CELEBRATION, Fla. , March 09, 2021 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary
Toggle Summary KemPharm to Present at the 33rd Annual Roth Conference
CELEBRATION, Fla. , March 04, 2021 (GLOBE NEWSWIRE) -- KemPharm , Inc. (NASDAQ: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced that Travis C. Mickle , Ph.D., President and CEO of KemPharm, will present at the 33 rd Annual
Toggle Summary KemPharm Announces FDA Approval of AZSTARYS™ (serdexmethylphenidate and dexmethylphenidate capsules, for oral use, CII), A New Once-Daily Treatment for ADHD
Conference Call and Live Audio Webcast Scheduled for Tomorrow, Wednesday, March 3 , at 8:30 a.m. ET CELEBRATION, Fla. , March 02, 2021 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ: KMPH), a specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, today
Toggle Summary KemPharm Receives FDA Clearance to Initiate KP879 Clinical Program for the Treatment of Stimulant Use Disorder
Financial Restructuring and Nasdaq Re-Listing Process Completed CELEBRATION, Fla. , Jan. 27, 2021 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ: KMPH), a specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, today announced that the U.S.